Kinase News and Research

RSS

TCD announces first patient treated in its TCD-717 Phase I trial

Traslational Cancer Drugs Pharma, S.L. (“TCD”) announced today that the first patient was treated on Friday the 18th of February with TCD-717 in a Phase I study performed in patients with advanced solid tumors. TCD-717 is a first-in-class, small molecule that precisely inhibits Choline Kinase Alpha, an enzyme heavily involved in the carcinogenic process. A total of 30 patients are planned to be treated in the trial, which will be conducted in accordance with FDA approval, in two leading medical centers in the U.S. The Principal Investigators are Dr. Julie Brahmer at the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital in Baltimore; and Dr. Patricia LoRusso at the Barbara Ann Karmanos Cancer Institute in Detroit.

28 Feb 2011

Scientists find p27Kip1 protein expression in adult and aged human inner ear

In collaboration with scientists and clinicians from the University of California Los Angeles, scientists from Sound Pharmaceuticals have found p27Kip1 to be expressed in the adult and aged human inner ear including the auditory and vestibular sensory organs.

25 Feb 2011

Study: AEG-1 expression predicts erlotinib treatment response in patients with EGFR-mutant lung cancer

Spanish researchers have identified a gene whose expression level strongly predicts how well certain lung cancer patients will respond to treatment with the drug erlotinib.

25 Feb 2011

New rapid and inexpensive test can effectively identify never-smoking group with lung adenocarcinoma

An inexpensive and rapid testing method can effectively identify a sub-group of never-smoking lung cancer patients whose tumors express a molecule associated with increased risk of disease progression or recurrence, US researchers have found.

25 Feb 2011

CST, Astellas Pharma enter commercialization partnership for cancer diagnostic, therapeutic products

Cell Signaling Technology, Inc. of Danvers, MA announced today a joint commercialization partnership with Astellas Pharma, Inc. of Tokyo, Japan focused on the delivery of personalized cancer therapeutics and diagnostics.

From Cell Signaling Technology 24 Feb 2011

Gilead Sciences signs definitive agreement to acquire Calistoga for $375 million

Gilead Sciences, Inc. and Calistoga Pharmaceuticals, Inc., a privately-held biotechnology company focused on the development of medicines to treat cancer and inflammatory diseases, today announced the signing of a definitive agreement pursuant to which Gilead will acquire Calistoga for $375 million.

22 Feb 2011

Cyclacel's CYC065 CDK inhibitor demonstrates potential against breast cancer resistant to trastuzumab

Cyclacel Pharmaceuticals, Inc., today announced the publication of preclinical data in the Proceedings of the National Academy of Sciences (PNAS), demonstrating that cyclin E plays a major role in making Human Epidermal growth factor Receptor 2 positive (HER2+) breast cancer resistant to trastuzumab (Herceptin®), a widely used medicine for breast cancer patients who test positive for HER2.

18 Feb 2011

FAK enzyme plays a key role in preparing lung tissue for metastatic development

A Massachusetts General Hospital study has identified a new role for an important enzyme in preparing lung tissue for the development of metastases.

17 Feb 2011

Deactivation of CRTC1 protein increases lifespan

Substantial evidence suggests that lifespan is increased if an organism restricts its daily calorie intake, a spartan regime that some say works by just making life seem longer. A team of scientists from the Salk Institute of Biological Studies has discovered a molecular switch flipped by hunger that could not only make longevity more appetizing but identify drug targets for patients with aging-related diseases such as type II diabetes or cancer.

17 Feb 2011

Study: Overexpression of EZH2 protein promotes breast cancer progression

An essential protein for normal stem cell renewal also promotes the growth of breast cancer stem cells when it's overproduced in those cells, researchers at The University of Texas MD Anderson Cancer Center report in the February edition of Cancer Cell.

16 Feb 2011

Scientists produce SR-3306 compound to protect brain cells from Parkinson's disease

Scientists from the Florida campus of The Scripps Research Institute have produced the first known compound to show significant effectiveness in protecting brain cells directly affected by Parkinson's disease, a progressive and fatal neurodegenerative disorder.

13 Feb 2011

Intellikine, PKD Foundation to investigate novel therapies for patients with PKD

Intellikine, a leader in the development of small molecule drugs targeting the PI3K/mTOR pathway, and the PKD Foundation today announced a collaboration to investigate novel, orally-available small molecule kinase inhibitors of the TORC1 and TORC2 complexes as a potential treatment for patients with polycystic kidney disease.

11 Feb 2011

Evotec signs definitive agreement to acquire all shares in Kinaxo

Evotec AG today announced the signing of a definitive agreement to acquire all shares in Kinaxo Biotechnologies GmbH, a Munich-based drug discovery alliance company supporting the development of targeted drugs.

9 Feb 2011

Cardiac enzyme elevations following CABG surgery is associated with worse prognosis

Patients who underwent coronary artery bypass graft surgery and had elevated levels of the cardiac enzymes creatine kinase or troponin in the 24 hours following surgery had an associated intermediate and long-term increased risk of death, according to a study in the February 9 issue of JAMA.

9 Feb 2011

CytRx's bafetinib helps reduce skeletal complications in cancer patients

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that results from a series of preclinical studies show that bafetinib may be useful in preventing bone loss in cancer patients who are at high risk for this event.

8 Feb 2011

Ansaris receives milestone payment for identification of kinase-related compound for cancer, autoimmune diseases

Ansaris announced today that it has received a milestone payment for the successful identification of a kinase-related compound under its drug discovery collaboration with Ono Pharmaceutical Co., Ltd. Ono will initiate the preclinical study of the identified compound. This collaboration between Ansaris and Ono was established to focus on the discovery of kinase-related compounds for the treatment of cancer, inflammatory and autoimmune diseases.

8 Feb 2011

Researchers identify CHK1 protein may serve as treatment target for neuroblastoma

After analyzing hundreds of proteins produced by the DNA of tumor cells, researchers have identified one protein that may be central to a new treatment for the often-fatal childhood cancer neuroblastoma. Oncologists hope to translate the finding into pediatric clinical trials of a drug that blocks the protein's activity.

7 Feb 2011

EntreMed announces publication of ENMD-2076 Phase 1 results against solid tumors in AACR journal

EntreMed, Inc., today announced the publication of key papers on the clinical and preclinical development of ENMD-2076, an Aurora A/angiogenic kinase inhibitor. The clinical data were published in the December 3, 2010 on-line issue of the American Association for Cancer Research journal, Clinical Cancer Research, and are expected to appear soon in the print version of the publication.

4 Feb 2011

Study finds contradictory role of RIP1 protein in the liver during sepsis

Researchers from Rhode Island Hospital have identified a protein that plays a dual role in the liver during sepsis. The protein, known as RIP1, acts both as a "death switch" and as a pro-survival mechanism. The ability to identify the triggers for these functions may play a key role in treating sepsis in the future. The study is published online in advance of print in the journal Shock.

3 Feb 2011

Agilent introduces first commercial RNA target enrichment system

Agilent Technologies, Inc., today introduced SureSelect RNA Capture Kits, the first commercial RNA target enrichment system enabling geneticists to focus on specific genomic loci or transcripts of research interest. The RNA capture kits make it possible to precisely measure expression levels of genes of interest and detect allelic-specific expression, splicing events and gene fusions.

3 Feb 2011

Kinase News and Research

TCD announces first patient treated in its TCD-717 Phase I trial

Scientists find p27Kip1 protein expression in adult and aged human inner ear

Study: AEG-1 expression predicts erlotinib treatment response in patients with EGFR-mutant lung cancer

New rapid and inexpensive test can effectively identify never-smoking group with lung adenocarcinoma

CST, Astellas Pharma enter commercialization partnership for cancer diagnostic, therapeutic products

Gilead Sciences signs definitive agreement to acquire Calistoga for $375 million

Cyclacel's CYC065 CDK inhibitor demonstrates potential against breast cancer resistant to trastuzumab

FAK enzyme plays a key role in preparing lung tissue for metastatic development

Deactivation of CRTC1 protein increases lifespan

Study: Overexpression of EZH2 protein promotes breast cancer progression

Scientists produce SR-3306 compound to protect brain cells from Parkinson's disease

Intellikine, PKD Foundation to investigate novel therapies for patients with PKD

Evotec signs definitive agreement to acquire all shares in Kinaxo

Cardiac enzyme elevations following CABG surgery is associated with worse prognosis

CytRx's bafetinib helps reduce skeletal complications in cancer patients

Ansaris receives milestone payment for identification of kinase-related compound for cancer, autoimmune diseases

Researchers identify CHK1 protein may serve as treatment target for neuroblastoma

EntreMed announces publication of ENMD-2076 Phase 1 results against solid tumors in AACR journal

Study finds contradictory role of RIP1 protein in the liver during sepsis

Agilent introduces first commercial RNA target enrichment system

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News